Biotech Strategy Blog Cancer Conferences New Products

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

View post

An in-depth look at Neon’s updated neoantigen vaccine data

Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?

View post

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess

View post

Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

A look at Amgen’s early oncology pipeline

An in-depth look at Neon’s updated neoantigen vaccine data

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

How F-star are optimising bispecific antibodies for cancer treatment

The Next Wave of IO with Dr Dan Chen

mRNA – the language of life

Dracarys! How T cell therapy is like Game of Thrones

A look at Amgen’s early oncology pipeline

An in-depth look at Neon’s updated neoantigen vaccine data

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?